Yellow Fever Virus: Flavivirus Deep Dive

Yellow fever is a mosquito-borne viral disease that most infected people survive, sometimes without noticing. In roughly one in seven of those who fall ill, though, it turns severe: the liver fails, the body starts to bleed, and the Centers for Disease Control and Prevention (CDC) says 30% to 60% of severe cases end in death. The World Health Organization (WHO) estimates 31,000 to 82,000 deaths a year in Africa and the Americas, even though a one-dose vaccine has existed since 1937. This article explains how the virus cycles between forests and cities, what it does to the body, and why outbreaks still happen.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.

What is the yellow fever virus?

Yellow fever virus (YFV) is a single-stranded, positive-sense RNA virus in the genus Flavivirus, family Flaviviridae. "Positive-sense" means the viral RNA can be read directly by a host cell's protein-making machinery, much like handing a factory a finished set of instructions instead of a blueprint that must first be converted. The genus name comes from the Latin flavus, "yellow," a nod to this disease. Its relatives include dengue, Zika, West Nile, and Japanese encephalitis viruses, which is why many of YFV's behaviors look familiar if you have read about those. For the general machinery of how a virus gets inside a cell and copies itself, see how viruses work from infection to replication.

The genome is translated into one long polyprotein, which cellular and viral enzymes then cut into three structural proteins (capsid C, pre-membrane prM, and envelope E) and seven non-structural proteins (NS1 to NS5, with several of them split into smaller pieces). The structural proteins build the particle. The non-structural proteins copy the RNA and help the virus dodge the cell's alarm systems. The envelope protein is the key for the outside world: it latches onto cells, drives the fusion that lets the genome in, and is the main target of the neutralizing antibodies that protect vaccinated people.

An analogy helps here. Think of the virus as a delivery van with a coded door lock. The envelope protein is the lock, the antibody is a key that jams it, and the vaccine is a way of letting the immune system practice making jamming keys before a real van shows up.

Which mosquitoes carry it?

WHO lists three mosquito groups as vectors: Aedes, Haemagogus, and Sabethes. They breed in domestic, semi-domestic, and forest settings, and they bite during the day, which is why insecticide-treated bed nets help less against yellow fever than they do against night-biting malaria mosquitoes (WHO fact sheet).

The mosquito species decides where the virus can go. Forest-canopy mosquitoes keep it circulating among monkeys. Aedes aegypti, which lives beside people and breeds in water stored in buckets, tires, and flower pots, is the one that can carry it through a city. The same container-breeding habit makes Ae. aegypti the vector of dengue and Zika. For a lighter look at why mosquitoes pick the people they pick, see why mosquitoes bite some people more.

Two transmission cycles: forest and city

Yellow fever persists in nature through distinct cycles. The difference between them determines whether a case is a sad but isolated event or the first spark of an epidemic.

The forest (sylvatic) cycle

In the forest cycle, the virus passes between monkeys and tree-dwelling mosquitoes. In the Americas the main vectors are Haemagogus and Sabethes species, and WHO's reports on the Brazilian outbreak describe exactly that pattern: virus-positive Haemagogus mosquitoes were isolated during the 2016-2017 season, which pointed to mainly forest transmission (WHO Disease Outbreak News, 11 February 2019).

Humans enter this cycle by accident, usually because they are working or traveling in forest: loggers, farmers, hunters, and tourists. A person bitten in the forest is a dead end for the virus if no Ae. aegypti is around to bite them next. When monkeys start dying, however, health authorities treat it as an early warning. The virus can kill New World monkeys outright, so dead howler monkeys and other primates serve as sentinels that the virus has reached an area. Brazil's 2016-2018 epidemic was preceded and accompanied by that kind of animal die-off.

The urban cycle

The urban cycle is where yellow fever becomes dangerous at scale. If a person infected in the forest returns to a town and is bitten by Ae. aegypti, the mosquito can pick up virus from the blood, and then pass it to the next person it bites. Now the monkeys are no longer needed. People infect mosquitoes, mosquitoes infect people, and the loop sustains itself for as long as there are enough mosquitoes and enough susceptible people.

WHO's yellow fever elimination strategy describes the risk in just those terms: urban outbreaks in Angola and the Democratic Republic of the Congo in 2016 were among the events that led to the strategy, with its emphasis on protecting cities and the workers most exposed to infection (WHO fact sheet).

Feature	Forest (sylvatic) cycle	Urban cycle
Main hosts	Monkeys and other non-human primates	Humans
Main mosquitoes	Haemagogus and Sabethes in the Americas; forest Aedes species in Africa	Aedes aegypti
Human role	Accidental, through forest exposure	Amplifying host
Typical pattern	Scattered cases, often among forest workers	Clusters and outbreaks in towns and cities
Control lever	Vaccinate people entering or living near forest	Vaccinate widely, reduce mosquito breeding sites

One more observation from Brazil is worth flagging. WHO reported that YFV was detected in Aedes albopictus mosquitoes captured in rural parts of two Minas Gerais municipalities in 2017, and said the significance of that finding needed further investigation. A detection in a wild-caught mosquito does not prove that the species is spreading the virus to people, so this remains an open question rather than an established route.

Why "yellow"? The liver takes the hit

The name refers to jaundice, the yellowing of skin and the whites of the eyes. Jaundice appears when the liver can no longer process bilirubin, a pigment made when old red blood cells are broken down. Normally the liver packages bilirubin for removal. If liver cells are dying in large numbers, bilirubin builds up in the blood and stains the tissues. If you want the background on what a healthy liver does, our explainer on how the liver works covers it.

YFV has a strong preference for liver cells, and the damage is distinctive. The Merck Manual notes that when yellow fever has not been diagnosed before death, it is confirmed at autopsy by the characteristic pattern of midzonal hepatocyte necrosis, meaning cell death concentrated in the middle zone of each liver lobule (Merck Manual Professional). The same source says a needle biopsy during illness is contraindicated, because the patient's clotting is impaired and bleeding is a real risk.

That impaired clotting follows directly from the liver injury. The liver manufactures most of the proteins that make blood clot. When it fails, bruising and bleeding follow, and laboratory results show low platelet counts, delayed clotting times, and a low white cell count. Kidney involvement shows up as protein in the urine, which Merck says occurs in 90% of patients and can be heavy enough to help distinguish yellow fever from viral hepatitis.

The clinical course: infection, remission, and the toxic phase

Yellow fever has a reputation for a "three-stage" illness. It is better to think of it as a spectrum. Many infections are mild or silent, and the full three-stage pattern describes only the people who go on to severe disease. CDC says most infected people have no symptoms or mild symptoms and fully recover.

Stage 1: Infection

After a bite from an infected mosquito, the incubation period is typically 3 to 6 days (WHO and CDC agree). The illness begins abruptly with fever, chills, severe headache, back pain, body aches, nausea, vomiting, fatigue, and weakness. WHO says this phase typically lasts three to four days. Merck describes fevers of 39 to 40 degrees Celsius, along with dizziness. The virus is abundant in the blood during these first days, so a sick person can infect a biting mosquito.

Many patients improve here, and mild disease may resolve after one to three days (Merck). Early symptoms are not specific. WHO notes they can resemble malaria, leptospirosis, viral hepatitis, dengue, and poisoning, which is part of the reason travelers' histories matter to the physician.

The pulse that does not keep up: Faget's sign

A classic bedside clue is relative bradycardia, known as Faget's sign after the 19th-century physician Jean-Charles Faget. In most fevers the pulse speeds up as the temperature rises. In yellow fever, Merck says the pulse is usually rapid at first and then becomes disproportionately slow for the degree of fever by about the second day.

Faget's sign is a hint, not a diagnosis. Relative bradycardia occurs in several other infections, so clinicians treat it as one clue among many, alongside travel history, jaundice, and laboratory tests. The underlying mechanism is not settled, so claims about exactly why the pulse lags should be treated cautiously.

Stage 2: Remission

In people who go on to severe illness, the fever falls two to five days after onset (Merck), and they feel better for a few hours to a day or so (CDC). Many patients stop here and recover, which is why the pause was historically read as recovery. Some who recover have weakness and fatigue that lasts for several months, according to CDC.

The reason for the remission is not well established. It is clinically important in either case: a person who feels better can be sent home just before the dangerous phase begins.

Stage 3: The toxic phase

For "1 out of 7 people who have the initial symptoms," in CDC's words, severe disease follows the brief remission. WHO puts the proportion at about 15%. Fever returns, the pulse often stays slow, and jaundice, bleeding, shock, and organ failure follow. Merck notes that jaundice, heavy protein in the urine, and upper abdominal tenderness with vomiting of blood often appear together after the fifth day. The old name for the dark, coffee-ground vomit of digested blood was vómito negro.

Merck describes a "malignant" form, in about 15% of cases, with delirium, intractable hiccups, seizures, coma, and multiple organ failure. Terminally, blood sugar can crash and potassium can climb. Bacterial infections, particularly pneumonia, can complicate recovery.

How deadly is it? Sources give slightly different figures, because the number depends on how severe cases are counted. WHO says about 50% of patients in the severe phase die within 7 to 10 days. CDC says 30% to 60% of people who develop severe disease die. Both agree that the figure applies to the severe minority, not to everyone infected.

Stage	Typical timing	What happens	Source
Incubation	3 to 6 days after the bite	No symptoms	WHO, CDC
Infection	Lasts about 3 to 4 days	Fever, headache, aches, nausea, vomiting; virus abundant in blood	WHO, Merck
Remission	Hours to about a day	Fever falls and the patient feels better	CDC
Toxic phase	In about 15% of infected people	Fever returns, jaundice, bleeding, shock, organ failure	WHO, CDC
Outcome of severe disease	Death usually within 7 to 10 days	About 50% die (WHO); 30% to 60% (CDC)	WHO, CDC

Diagnosis and treatment

Diagnosis rests on laboratory testing because the early picture overlaps with so many other illnesses. WHO says that in the early stage the virus can be found in blood by RT-PCR (a test that detects viral RNA). Later, the immune response can be detected with ELISA or a plaque reduction neutralization test (PRNT). Merck adds that RT-PCR is most useful within seven days of onset, and that vaccination history matters when interpreting antibody results, since IgM antibodies to the vaccine virus can persist for years.

There is no approved antiviral. WHO says treatment is supportive: rest, fluids, management of fever, and care for liver and kidney failure, plus antibiotics for secondary bacterial infection. It adds that the antiviral sofosbuvir and a monoclonal antibody called TY014 are recommended only in research settings. Jaundice marks severe disease and usually calls for hospitalization, often in intensive care. Merck lists vitamin K for bleeding and stomach-acid suppression to reduce gastrointestinal bleeding in hospitalized patients.

The treatment picture explains why public health officials talk about yellow fever almost entirely in terms of prevention. Once severe disease begins, medicine can support the body, but it cannot clear the virus.

How a mosquito theory beat a century of confusion

For much of the 18th and 19th centuries, yellow fever was blamed on foul air, contaminated ships, and "miasma." The toll was enormous. Gavi's historical account reports about 20,000 deaths in the lower Mississippi valley in 1878, and that during the Spanish-American War of 1898 more than four times as many US soldiers died of yellow fever as were killed in combat (Gavi VaccinesWork).

The breakthrough came in Cuba. The Cuban physician Carlos Finlay had championed the mosquito theory for about twenty years, but he could not prove it. In 1900 a US Army Yellow Fever Commission led by Walter Reed arrived in Cuba and tested the idea on human volunteers. The details of those experiments, including the deaths of investigators and the ethical questions they raise, are in our article on Walter Reed's yellow fever experiments in Cuba.

Date	Event	Source
June 1900	US Army Yellow Fever Commission arrives in Cuba	Gavi
31 August 1900	Private William Dean is bitten by a deliberately infected mosquito and is sick within five days	Gavi
25 September 1900	Dr. Jesse Lazear, aged 34, dies of yellow fever	Gavi
1901	William Gorgas begins mosquito control in Havana; yellow fever deaths, which had averaged 462 a year, fall to tens	Gavi
January 1903	Gorgas tells the US Senate that Cuba is free of yellow fever	Gavi
Early 1905	At Panama, Gorgas's mosquito-control detachment of 4,000 goes to work	Gavi
December 1905	Deaths among workers stop; canal construction can continue	Gavi
1914	The Panama Canal opens	Gavi

The Panama story is often told with exaggeration, so it helps to stick to documented points. Gavi reports that the Americans took over the French infrastructure in 1904, that tens of thousands of workers died across the project, and that an estimated 85% fell ill. Gorgas's 1901 measures in Havana were practical rather than glamorous: inspecting homes, mosquito-proofing water containers, treating drinking water, and burning pyrethrum powder to kill adult mosquitoes. Before there was any vaccine, controlling the vector alone had broken the urban cycle.

The 17D vaccine: one dose, lifelong protection

Controlling mosquitoes works, but it demands constant effort. A vaccine moved the problem from the environment to the individual. The 17D vaccine, developed in the 1930s at the Rockefeller Foundation by South African-born virologist Max Theiler and colleagues, remains in use today.

How it was made

The story starts with a virus isolated from a patient. Theiler's Nobel-era history, as told in a 2007 article in the Journal of Experimental Medicine, traces how the Asibi strain of YFV was passed repeatedly through animal tissue and then chicken embryo tissue. The article reports that an attenuated variant emerged between roughly the 89th and 114th passages, and that the resulting strain had lost the ability to cause the neurological and liver damage that wild virus does (Norrby, J Exp Med 2007). Sources differ on the total number of passages in the 17D lineage, so a single count is best avoided.

Attenuation is like taking a well-trained guard dog and breeding out its aggression while keeping its recognizable bark. The weakened virus still replicates a little, which is enough to teach the immune system what the real thing looks like, but it cannot cause yellow fever in a healthy person. Because it replicates, 17D is called a live attenuated vaccine, and that is the source of both its strength (one dose, long-lasting protection) and its restrictions (it is unsuitable for some people with weakened immunity).

Norrby's article gives the timeline: Theiler joined the Rockefeller Foundation's yellow fever program in 1930, the vaccine was developed in 1937, and a first field trial followed in Brazil in 1938. Theiler was awarded the Nobel Prize in Physiology or Medicine in 1951. Norrby describes it as the first and only Nobel Prize for a virus vaccine, as of his 2007 writing, and reports that more than 400 million doses of 17D had been used over 60 years.

How well it works

WHO says a single dose provides lifelong protection with no booster needed. Immunity develops in 80% to 100% of people within 10 days and in more than 99% within 30 days. Merck gives an efficacy of 95% and advises receiving the vaccine at least 10 days before travel. The slightly different figures reflect different measures: the share of people with protective antibodies versus protection against disease.

Boosters are not entirely off the table. CDC lists groups for whom a booster may be considered, such as people who received a stem cell transplant after their last dose, and travelers vaccinated at least 10 years earlier who face higher-risk exposure (CDC clinician vaccine page). Merck adds that some countries may require boosters for entry even though WHO does not recommend routine ones. For the broader immunology of why a live vaccine can leave long-lived memory, see how vaccines train memory B cells and how vaccines work.

Who should not receive it, and the rare serious risks

The vaccine is not for everyone. WHO does not recommend it for infants under 9 months, for pregnant women (except during outbreaks), for people with severe egg allergy, or for people with severe immunodeficiency or thymus disorders, and it says that above 60 years the risk-benefit balance needs careful consideration. CDC's clinician guidance lists age under 6 months as a contraindication and ages 6 to 8 months and 60 and older as precautions. Merck lists uncontrolled HIV (CD4 below 200 per cubic millimeter), thymus disorders with abnormal immune function, primary immunodeficiencies, malignancy, solid organ transplant, and immunosuppression among contraindications.

The reason for the caution is a rare reaction called yellow fever vaccine-associated viscerotropic disease (YEL-AVD), in which the vaccine virus behaves like a mild version of the wild virus and spreads to organs. A CDC report in its Morbidity and Mortality Weekly Report puts the US risk at approximately 0.4 cases per 100,000 doses distributed, rising to one per 100,000 for travelers aged 60 and older and 2.3 per 100,000 for those aged 70 and older. It also notes that older age and thymic disease are linked to higher risk (CDC MMWR).

Group (US travelers)	YEL-AVD cases per 100,000 doses distributed
All ages	About 0.4
Aged 60 and older	About 1
Aged 70 and older	2.3

The same report describes a woman in her 60s with no known thymic disease who died after receiving yellow fever and typhoid vaccines. At autopsy her thymus was enlarged, and tests suggested undiagnosed myasthenia gravis. The authors concluded that her age and hidden thymic disease likely predisposed her. The numbers show why decisions about vaccination, particularly for older travelers, are made case by case with a clinician, weighing the actual risk of exposure at the destination against these small but real vaccine risks. This is general information, not personal medical guidance.

Vaccination certificates

Under the International Health Regulations (2005), countries may require proof of vaccination from travelers, and medical exemptions have to be certified, according to WHO. In practice, the yellow-card certificate is one of the few vaccination documents that international travel rules still formalize.

Outbreaks that changed how the world responds

Angola and the Democratic Republic of the Congo, 2015-2016

The outbreak began in Angola in late 2015 and spread to the DRC, with imported cases reaching other countries. It was a large urban outbreak, and a reactive vaccination campaign in Luanda used stockpiled vaccine. In the DRC, the response included a fractional-dose campaign in Kinshasa: smaller-than-standard doses stretched to cover more people when full-dose supplies ran short. WHO's Emergency Committee noted that this exceptional strategy "achieved very high population coverage," while the effect on duration of immunity was still to be assessed. By its meeting statement of 31 August 2016, there had been no confirmed cases in Angola since 23 June and none in the DRC since 12 July. Imported cases in China and Kenya did not lead to further transmission (WHO Emergency Committee statement).

The Chinese cases mattered because China has plenty of Aedes mosquitoes but, as far as is known, no established yellow fever transmission. Their failure to ignite an outbreak was a relief, but also a reminder of how many things have to go wrong, or right, before a virus finds a new home.

Brazil, 2016-2018

Brazil's outbreak was mostly forest-driven but unusually close to big cities. WHO's later summary describes two seasonal waves.

Season	Confirmed human cases	Deaths
2016-2017	778	262
2017-2018	1,376	483

Source: WHO Disease Outbreak News, 11 February 2019. Figures are WHO's summary totals for each seasonal period.

A Eurosurveillance analysis written in March 2018 gives a feel for the 2017-2018 wave as it unfolded. From July 2017 to 13 March 2018 there were 920 confirmed human cases and 300 deaths, concentrated in Minas Gerais (415 cases), São Paulo (376), and Rio de Janeiro (123). Authorities also recorded 617 epizootics, outbreaks of illness among monkeys, 502 of them in São Paulo state, which served as early warnings. About 17.5 million people in Brazil had been vaccinated by 13 March 2018 (Gossner et al., Eurosurveillance 2018).

The Brazilian outbreak had two lessons. First, vaccination strategy can be adapted in the middle of an epidemic. WHO reports that Brazil has used a single-dose scheme since April 2017 and used fractional-dose vaccination in 77 high-risk municipalities during the 2017-2018 season. Second, travelers are part of the story. The Eurosurveillance authors documented five unvaccinated European travelers infected in early 2018, one of whom died, with three having visited the island resort of Ilha Grande. They also noted six travel-related cases reported by Argentina and Chile. Local transmission in continental Europe was judged very unlikely, because the main urban vector, Ae. aegypti, is absent there.

The Asia puzzle

Yellow fever circulates in Africa and the Americas but has not established itself in Asia, even though Aedes aegypti is common there and dengue thrives. Researchers have proposed several explanations, and none has fully settled the question.

• Cross-immunity. Prior infection with dengue or other flaviviruses may give partial protection against yellow fever. Some laboratory animal studies have tested this idea, with mixed or limited results.
• Vector differences. Asian Ae. aegypti populations might be less efficient at transmitting YFV, or dengue might outcompete yellow fever inside the mosquito.
• Other factors. Dengue and yellow fever coexist in both Africa and South America, so cross-immunity alone cannot be the whole story. Differences in viral genotypes have also been proposed.

The honest summary is that this is an open question. The cross-immunity evidence comes mainly from animal models and small human studies, and no hypothesis has been conclusively confirmed. For public health planners, the practical point is not which hypothesis is right but that the absence of yellow fever in Asia is not proof that it could never arrive. The 2016 imported cases in China remain the best reminder.

How yellow fever compares with its relatives

Several of the facts above are easiest to see side by side. This table is intentionally qualitative: case counts differ so much by year and surveillance quality that single numbers for dengue and Zika would mislead.

Feature	Yellow fever	Dengue	Zika
Virus family	Flaviviridae	Flaviviridae	Flaviviridae
Key urban vector	Ae. aegypti	Ae. aegypti	Ae. aegypti
Forest cycle with monkeys	Yes, well documented	Not a major driver of human disease	Described
Jaundice as a hallmark	Yes	Not typical	Not typical
Faget's sign (relative bradycardia)	Classic clue	Reported in some patients	Not a recognized feature
Specific antiviral	None	None	None
Effective single-dose vaccine	Yes (17D)	Different vaccines with limits	No licensed vaccine
Known birth-defect syndrome	No	Not a classic feature	Yes (congenital Zika syndrome)

Each of these rows is described in more detail in the linked articles on dengue and Zika. Readers interested in other mosquito-borne neighbors may also look at West Nile virus and the broader question of how viruses jump from animals to humans.

Where the world stands now

WHO estimates that 67,000 to 173,000 severe infections and 31,000 to 82,000 deaths occur each year in Africa and the Americas, most of them in Africa. It classifies 27 African and 13 Latin American countries as high-risk for outbreaks. It also notes that in an outbreak the true number of cases may be 10 to 250 times higher than the number reported, which is a reminder of how patchy surveillance is where the disease is most active.

The older figures of 200,000 cases and 30,000 deaths a year, which still circulate in textbooks and articles, come from an earlier estimate of the toll in non-immunized populations. WHO's current ranges are model-based and wide, and the best reading is that the burden is in the tens of thousands of deaths a year, not an exact count.

The global response is organized under the Eliminate Yellow Fever Epidemics (EYE) strategy, which runs from 2017 to 2026, is steered by Gavi, UNICEF, and WHO, and aims to end yellow fever epidemics by the end of 2026. Its three objectives are mass vaccination campaigns alongside routine childhood immunization in high-risk countries, preparedness for urban outbreaks and protection of high-risk workers, and early detection with rapid response. Merck makes the underlying arithmetic explicit: maintaining at least 80% vaccination coverage in at-risk populations is the most effective way to prevent outbreaks.

What people often get wrong

"Yellow fever is a disease of the past." The Panama Canal story makes it sound historical, but WHO's burden estimates are current, and Brazil's 2016-2018 outbreak produced thousands of cases in an era with a good vaccine.

"Everyone who gets it dies or turns yellow." Most infections are mild or silent. Severe disease affects roughly one in seven people who have initial symptoms, and the high fatality figures apply to that subgroup.

"Feeling better means it is over." The remission period is real, and it is the reason patients who are felt to be recovering need follow-up until the picture is clear.

"You need a booster every 10 years." WHO's position is that one dose is enough for lifelong protection. Some countries and some special groups follow different rules, so travelers should check the entry requirements of the destination.

"A vaccine that uses a live virus must be dangerous." Serious reactions exist, and the MMWR figures above quantify them, but they are rare and concentrated in identifiable groups such as older adults and people with thymus disease. The risk calculation changes when someone is traveling to or living in an area with active transmission.

What this means

Yellow fever shows how a disease can be both well understood and stubbornly present. We know the virus, the mosquitoes, the liver pathology, and the vaccine that stops it. The remaining difficulty is logistics: reaching enough people in time, keeping vaccine stocks adequate when a city outbreak erupts, and catching the first monkey die-off or the first cluster before it becomes an epidemic.

The record of the last decade, from Luanda to São Paulo, suggests the biggest threat is not a mysterious new property of the virus. It is gaps in vaccination coverage meeting a mosquito that thrives in cities. That is a solvable problem in principle, which is why elimination of epidemics is a stated goal rather than a fantasy, and also why the open question of Asia deserves attention before the answer is discovered the hard way.

Frequently asked questions

Q: Why does yellow fever cause jaundice when dengue usually does not? A: Yellow fever virus strongly targets liver cells, causing a characteristic pattern of cell death in the middle of each liver lobule. When the liver cannot clear bilirubin, the pigment builds up and yellows the skin and eyes. Dengue can affect the liver too, but severe dengue is more associated with plasma leakage and low platelet counts than with jaundice.

Q: What is Faget's sign? A: It is relative bradycardia: a pulse that is slower than the fever would normally produce. According to the Merck Manual, the pulse is usually rapid at first and then becomes disproportionately slow by about day 2. It is a useful clue in yellow fever, but it also occurs in other infections and is not diagnostic by itself, and the mechanism is not settled.

Q: How long does protection from the 17D vaccine last? A: WHO says a single dose gives lifelong protection with no booster needed. Immunity develops in 80% to 100% of people within 10 days and in over 99% within 30 days. CDC lists a few situations in which a booster may be considered, such as after a stem cell transplant or for higher-risk travelers vaccinated at least 10 years earlier.

Q: Who should not get the yellow fever vaccine? A: WHO does not recommend it for infants under 9 months, pregnant women (except in outbreaks), people with severe egg allergy, or people with severe immunodeficiency or thymus disorders, and it advises careful risk-benefit review above age 60. A clinician or travel-health clinic should assess individual circumstances. This answer is general information, not a personal recommendation.

Q: Is there a drug that treats yellow fever? A: No approved antiviral exists. Care is supportive: fluids, fever control, management of liver and kidney failure, and antibiotics for secondary bacterial infections. WHO says sofosbuvir and the monoclonal antibody TY014 are recommended only in research settings, which is why prevention through vaccination is emphasized.

Q: Why hasn't yellow fever become established in Asia? A: Nobody knows for certain. Proposed explanations include partial cross-immunity from dengue and other flaviviruses, lower transmission efficiency in Asian Ae. aegypti, and competition between viruses inside the mosquito. Dengue and yellow fever coexist in Africa and South America, so no single factor looks sufficient. The question remains open.

Q: What is the difference between the forest and urban cycles? A: In the forest cycle, the virus moves between monkeys and tree-dwelling mosquitoes, and people are infected by accident. In the urban cycle, Aedes aegypti carries the virus directly from person to person. The urban cycle can produce large outbreaks, which is why a single infected traveler arriving in a poorly vaccinated city is a public health concern.

---

Sources

1. World Health Organization. Yellow fever. Fact sheet (updated 20 October 2025). https://www.who.int/news-room/fact-sheets/detail/yellow-fever
2. Centers for Disease Control and Prevention. Signs and Symptoms of Yellow Fever. https://www.cdc.gov/yellow-fever/signs-symptoms/index.html
3. Centers for Disease Control and Prevention. Yellow Fever Vaccine: Information for Healthcare Providers. https://www.cdc.gov/yellow-fever/hcp/vaccine/index.html
4. CDC. Fatal Yellow Fever Vaccine-Associated Viscerotropic Disease, Oregon, September 2014. MMWR. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6410a5.htm
5. Merck Manual Professional Version. Yellow Fever. https://www.merckmanuals.com/professional/infectious-diseases/arboviruses-arenaviridae-and-filoviridae/yellow-fever
6. Norrby E. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. Journal of Experimental Medicine, 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC2118520
7. Gavi VaccinesWork. Yellow Fever and the Panama Canal. https://www.gavi.org/vaccineswork/yellow-fever-and-panama-canal
8. WHO. Disease Outbreak News: Yellow fever, Brazil, 11 February 2019. https://www.who.int/emergencies/disease-outbreak-news/item/11-february-2019-yellow-fever-brazil-en
9. Gossner CM, et al. Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, July 2017 to March 2018. Eurosurveillance 2018;23(11). https://pmc.ncbi.nlm.nih.gov/articles/PMC5861590
10. WHO. Statement on the 2nd meeting of the IHR Emergency Committee on yellow fever (31 August 2016). https://www.who.int/mediacentre/news/statements/2016/yellow-fever-second-ec/en/

---

Read next:

• Zika Virus Explained: Symptoms, Risks & Outbreak
• Chikungunya Virus Explained
• Japanese Encephalitis Virus: A Complete Guide